China Pharma Holdings, Inc. (CPHI)

NYSEAMERICAN: CPHI · Real-Time Price · USD
0.200
0.00 (0.20%)
Dec 11, 2024, 4:00 PM EST - Market closed
0.20%
Market Cap 3.75M
Revenue (ttm) 5.54M
Net Income (ttm) -4.74M
Shares Out 19.25M
EPS (ttm) -0.35
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 159,510
Open 0.190
Previous Close 0.200
Day's Range 0.187 - 0.200
52-Week Range 0.170 - 0.700
Beta 0.66
Analysts n/a
Price Target n/a
Earnings Date Nov 13, 2024

About CPHI

China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products to hospitals and private retailers in the People’s Republic of China. The company provides products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain;... [Read more]

Sector Healthcare
CEO Zhilin Li
Employees 231
Stock Exchange NYSEAMERICAN
Ticker Symbol CPHI
Full Company Profile

Financial Performance

In 2023, China Pharma Holdings's revenue was $7.01 million, a decrease of -13.48% compared to the previous year's $8.10 million. Losses were -$3.08 million, -22.50% less than in 2022.

Financial Statements

News

China Pharma Holdings, Inc. expects to launch its Dry Eye Disease Therapeutic Device in the first quarter of 2025

HAIKOU, China , Aug. 19, 2024 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma", or the "Company"), an NYSE American-listed corporation with a fully-integrated specialt...

4 months ago - PRNewsWire

China Pharma Holdings Inc. Announces 1-for-5 Reverse Stock Split

HAIKOU, China , Feb. 23, 2024 /PRNewswire/ -- China Pharma Holdings Inc. ("China Pharma" or the "Company") (NYSE American: CPHI) reported that it expects to implement a 1-for-5 reverse stock split on ...

10 months ago - PRNewsWire

China Pharma Holdings, Inc. Announced the Completion of Third Party Testing of Dry Eye Disease Therapeutic Device

HAIKOU, China , Nov. 29, 2023 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma", or the "Company"), an NYSE American-listed corporation with a fully-integrated specialt...

1 year ago - PRNewsWire

China Pharma's Candesartan Hypertension Product Passes the Quality and Efficacy Consistency Evaluation of Generic Drugs

HAIKOU, China , Aug. 9, 2023 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), a specialty pharmaceutical company, today announced that its who...

1 year ago - PRNewsWire

China Pharma Holdings Inc. Announces 1-for-10 Reverse Stock Split

HAIKOU, China , Feb. 24, 2023 /PRNewswire/ -- China Pharma Holdings Inc. ("China Pharma" or the "Company") (NYSE American: CPHI) reported that it expects to implement a 1-for-10 reverse stock split on...

1 year ago - PRNewsWire

China Pharma Holdings, Inc. Announced the Launch of N95 Medical Protective Mask

HAIKOU, China , Dec. 28, 2022 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma", the "Company" or "We"), an NYSE American-listed corporation with a fully-integrated spe...

2 years ago - PRNewsWire

China Pharma Holdings, Inc. Announced that several products are included in the Catalogue of Medicines for People Infected with COVID-19

HAIKOU, China , Dec. 15, 2022 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma", the "Company" or "We"), an NYSE American-listed corporation with a fully-integrated spe...

2 years ago - PRNewsWire

China Pharma Holdings, Inc. Announced the Acquisition of Dry Eye Disease Therapeutic Device Project

HAIKOU, China , Dec. 5, 2022 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma", the "Company" or "We"), an NYSE American-listed corporation with a fully-integrated spec...

2 years ago - PRNewsWire

China Pharma Announces Receipt of Noncompliance Notice from NYSE American

HAIKOU, China , Dec. 2, 2022 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), a specialty pharmaceutical company, today announced that on Dece...

2 years ago - PRNewsWire

China Pharma Announces Receipt of Notification of NYSE American Listing Deficiency

HAIKOU, China , Oct. 1, 2022 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI; the "Company") today announced that on September 26, 2022, the Company received notification (the "Defici...

2 years ago - PRNewsWire

China Pharma Announced the Submission of a Plan of Compliance to NYSE American

HAIKOU, China , July 18, 2022 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), a specialty pharmaceutical company, today announced that on Jul...

2 years ago - PRNewsWire

China Pharma Holdings, Inc. Reports Fiscal Year 2021 Financial Results

HAIKOU, China, March 31, 2022 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), an NYSE American-listed corporation with a fully-integrated spe...

2 years ago - PRNewsWire

China Pharma Holdings, Inc. Reports Third Quarter 2021 Financial Results

HAIKOU, China, Nov. 12, 2021 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI)  ("China Pharma," the "Company" or "We"), an NYSE American-listed corporation with a fully-integrated spe...

3 years ago - PRNewsWire

China Pharma Holdings, Inc. Reports Second Quarter 2021 Financial Results

HAIKOU, China, Aug. 13, 2021 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI)  ("China Pharma," the "Company" or "We"), an NYSE American-listed corporation with a fully-integrated spe...

3 years ago - PRNewsWire

China Pharma's Candesartan Hypertension Product Passes Bioequivalence Tests and the Company Plans to Apply for NMPA Approval

HAIKOU, China , Aug. 5, 2021 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), a specialty pharmaceutical company, today announced that its Can...

3 years ago - PRNewsWire

China Pharma to Launch Highly Purified NMN+PQQ Product

HAIKOU, China, June 9, 2021 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), a specialty pharmaceutical company, today announced plans to laun...

3 years ago - PRNewsWire

China Pharma Holdings, Inc. Reports 33% YoY Increase in First Quarter 2021 Revenue

HAIKOU, China, May 14, 2021 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), a specialty pharmaceutical company, today announced financial res...

3 years ago - PRNewsWire

China Pharma Expects Considerable Increase in Growth Opportunities Related to Hainan Free Trade Port

HAIKOU, China, April 19, 2021 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), a specialty pharmaceutical company, commented on the policy sta...

3 years ago - PRNewsWire

China Pharma Holdings, Inc. Reports Fiscal Year 2020 Financial Results

HAIKOU CITY, China , March 26, 2021 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI)  ("China Pharma," the "Company" or "We"), an NYSE American-listed corporation with a fully-integra...

4 years ago - PRNewsWire

China Pharma Holdings Inc. (CPHI) CEO Zhilin Li on Q4 2019 Results - Earnings Call Transcript

China Pharma Holdings Inc. (CPHI) CEO Zhilin Li on Q4 2019 Results - Earnings Call Transcript

5 years ago - Seeking Alpha

China Pharma's (CPHI) CEO Zhilin Li on Q2 2019 Results - Earnings Call Transcript

China Pharma's (CPHI) CEO Zhilin Li on Q2 2019 Results - Earnings Call Transcript

5 years ago - Seeking Alpha

China Pharma Holdings, Inc. (CPHI) CEO Zhilin Li on Q1 2019 Results - Earnings Call Transcript

China Pharma Holdings, Inc. (CPHI) CEO Zhilin Li on Q1 2019 Results - Earnings Call Transcript

6 years ago - Seeking Alpha

China Pharma Holdings, Inc. (CPHI) CEO Zhilin Li on Q4 2018 Results - Earnings Call Transcript

China Pharma Holdings, Inc. (CPHI) CEO Zhilin Li on Q4 2018 Results - Earnings Call Transcript

6 years ago - Seeking Alpha